Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer  

作　　者：Mary P.Martos Haleh Amirian Erin M.Dickey Edmond W.Box Nipun B.Merchant Peter J.Hosein Caitlin A.Hester Jashodeep Datta 

机构地区：[1]Department of Surgery,University of Miami Miller School of Medicine,Miami,FL,USA [2]Sylvester Comprehensive Cancer Center,Miami,FL,USA [3]Department of Medicine,University of Miami Miller School of Medicine,Miami,FL,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第2期325-328,共4页肝胆外科与营养（英文）

摘　　要：Pancreatic ductal adenocarcinoma(PDAC)is a devastating malignancy,owing in part to the fact that most patients present with advanced disease with only 20%eligible for surgical resection.Moreover,the dismal oncologic outcomes achieved with surgery alone,coupled with the almost ubiquitous distant recurrence in operable PDAC patients,have mandated a multimodal approach for this disease.The advent of effective combination chemotherapy regimens delivered increasingly in the perioperative setting,safety and technical mastery of pancreatectomy,and growing appreciation of the molecular underpinnings in PDAC have resulted in gradual but consistent improvements in disease-specific survival and overall survival(OS)in patients with localized PDAC(1).

关 键 词：Pancreatic adenocarcinoma pancreatic cancer prognostic model preoperative factors patient stratification 

分 类 号：R735.9[医药卫生—肿瘤]